InvionIVX 
0.00%24h
Invion (IVX) Stock Overview
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
IVX Stock Information
Invion (IVX) Price Chart
Invion Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.002029605174140124 | N/A |
| Market Cap | $13.03M | N/A |
| Shares Outstanding | 6.42B | 4.94% |
| Employees | 0 | N/A |
| Shareholder Equity | 18.40M | -6.04% |
Valuation | 2023 | Change |
|---|---|---|
| P/S Ratio | 4.69 | N/A |
| P/B Ratio | 0.71 | N/A |
| P/FCF | -4.39 | N/A |
Growth | 2023 | Change |
|---|---|---|
| CAPEX | -51.30K | N/A |
| Return on Equity | -0.0594 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $2.78M | N/A |
| Earnings | -$1.09M | N/A |
| Free Cash Flow | -$2.97M | N/A |
| Gross Margin | 1.00 | N/A |
| Operating Margin | -0.4016 | N/A |
| Net income margin | -0.3934 | N/A |
| FCF Margin | -1.07 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $12.89M | N/A |
| Cash on Hand | $2.76M | N/A |
| Debt to Equity | 0.0239 | 49.75% |
| Current Ratio | $8.85 | -52.66% |
